Not applicableAvailableNCT07643831
What this trial is testing
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer
Who this might be right for
ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
Genentech, Inc.